Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Down 5.5% in November

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 5,680,000 shares, a decline of 5.5% from the October 31st total of 6,010,000 shares. Based on an average daily trading volume, of 946,800 shares, the short-interest ratio is presently 6.0 days.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 12,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares of the company's stock, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Molly Harper sold 17,500 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CPRX. Arizona State Retirement System lifted its position in Catalyst Pharmaceuticals by 2.2% in the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company's stock valued at $461,000 after acquiring an additional 654 shares in the last quarter. GAMMA Investing LLC lifted its stake in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 681 shares during the period. XTX Topco Ltd boosted its holdings in shares of Catalyst Pharmaceuticals by 7.5% during the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company's stock valued at $172,000 after acquiring an additional 773 shares during the last quarter. Strategic Advocates LLC grew its stake in shares of Catalyst Pharmaceuticals by 6.5% in the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company's stock worth $219,000 after acquiring an additional 864 shares during the period. Finally, Sei Investments Co. boosted its holdings in Catalyst Pharmaceuticals by 1.3% in the second quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company's stock worth $1,308,000 after purchasing an additional 1,098 shares during the last quarter. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ CPRX traded down $0.82 during trading on Tuesday, reaching $21.71. The company had a trading volume of 902,287 shares, compared to its average volume of 1,185,535. The business's 50-day moving average is $21.30 and its 200 day moving average is $18.83. The stock has a market cap of $2.59 billion, a PE ratio of 19.09, a P/E/G ratio of 3.40 and a beta of 0.75. Catalyst Pharmaceuticals has a 12-month low of $13.00 and a 12-month high of $24.27.

Wall Street Analyst Weigh In

Several research firms have commented on CPRX. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, August 9th. Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, November 11th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price objective for the company. Finally, Citigroup raised their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.